Mayinglong Pharmaceutical Group Co Ltd operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Mayinglong Pharmaceutical Group Co Ltd with three other
companies in this sector in China:
Shandong Shanda Wit Science and Technology Co Ltd
sales of 1.77 billion Chinese Renmimbi [US$260.93 million]
of which 68%
Jiang Zhong Pharmaceutical Co Ltd
(1.75 billion Chinese Renmimbi [US$257.87 million]
of which 99%
was Medical Industry), and
Shanghai Shenqi Pharmaceutical Investment Management CoLtd
(1.74 billion Chinese Renmimbi [US$256.28 million]
of which 73%
Mayinglong Pharmaceutical Group Co Ltd reported sales of 1.75 billion Chinese Renmimbi (US$258.47 million)
December of 2017.
decrease of 16.7%
versus 2016, when the company's sales were 2.10 billion Chinese Renmimbi.